Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 727

recruiting
3 968
countries
28
conditions
2 103

10 282 trials match your criteria

Dementia Alzheimer's type

Not recruiting

Study of BAN2401 (lecanemab) in people with early stage Alzheimer's disease to evaluate its effectiveness in preventing disease progression

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Florquinitau (18F)

Advanced systemic mastocytosis

Not recruiting

Study on the Safety and Effectiveness of Bezuclastinib for Patients with Advanced Systemic Mastocytosis

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:3,4-Dimethyl-N-(2-Phenyl-1H-Pyrrolo[2,3-B]Pyridin-5-Yl)-1H-Pyrazole-5-Carboxamide

Relapsing-remitting multiple sclerosis

Not recruiting

Study comparing stem cell transplantation versus alemtuzumab, cladribine or ocrelizumab in patients with aggressive relapsing-remitting multiple sclerosis

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:Alemtuzumab

Breast cancer metastatic+2

Not recruiting

Study of Paclitaxel, Carboplatin, and Durvalumab with or without Oleclumab for Patients with Untreated Advanced Triple-Negative Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Carboplatin

Ovarian cancer

Not recruiting

Study on Eye Health During Treatment with Mirvetuximab Soravtansine, Brimonidine Tartrate, and Prednisolone Acetate for Patients with Recurrent Ovarian Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Brimonidine Tartrate

Myelodysplastic syndrome

Not recruiting

Study of Tamibarotene and Azacitidine Treatment in Newly Diagnosed Adults with RARA-positive Higher-risk Myelodysplastic Syndrome (MDS)

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine

Adenocarcinoma gastric

Not recruiting

Study of Trastuzumab Deruxtecan for Patients with HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer After Trastuzumab Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel

Non-small cell lung cancer

Not recruiting

Study of Tiragolumab, Atezolizumab, and Pembrolizumab for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Mitochondrial DNA depletion

Not recruiting

Study of Doxecitine and Doxribtimine Oral Solution for Treatment of Patients with Thymidine Kinase 2 (TK2) Deficiency Who Have Previously Received Treatment

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Doxecitine

Bladder transitional cell carcinoma

Not recruiting

Study of TAR-200 and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Not Undergoing Radical Cystectomy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cetrelimab

Non-small cell lung cancer

Not recruiting

Study of SKB264 and Pembrolizumab for Treating Patients with Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Carbonate

Gastrointestinal melanoma+7

Not recruiting

Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with BRAF V600E/K Mutation-Positive Melanoma After Anti-PD-1 Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Binimetinib

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.